EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.

EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.
  • Home
  • Technology
    全部 Engineering expression platform Antibody Humanization Antibody Affinity Maturation Phage Display Antibody Library Bispecific Antibody CAR-T
  • About Us
    全部 Corporate Honors Introduction Team History
  • Product
    全部 Drug Discovery Scientific research products Project cooperation Alpaca natural nanoantibody phage display library Alpaca antigen injection and alpaca blood collection Antibody customization Antibody humanization maturation of antibody affinity Human natural antibody phage display library YK012 Diagnostic and therapeutic neutralizing antibodies against COVID-19
  • News
  • Job
  • Contact

  1. Home
  2. News

The "patent authorization of bispecific antibody" was approved

2020-02-10 09:53:05 admin 2

MetInfo enterprise content manager system | MetInfo CMS


  • Previous : Special fund support for epidemic prevention scientific research and emergency production in Haidian District in 2020
  • Next : The first batch of new technology enterprises to fight against COVID-19 epidemic in Zhongguancun
  • News

为你推荐

  • Nature Major findings: lower affinity agonist antibody is more effective
  • Phase I clinical trial project of YK012 for injection was officially launched
  • The 2022 year-end summary meeting ended successfully
  • The leaders went to the Sino-Science Life Science Industrial Park for investigation
  • Fight against COVID-19 - EXCYTE is in action

版权所有 2017-2026 京ICP备17063430号

5 Kaituo Road, Haidian District, Beijing (Zhongguancun Bio-medicine Park) Room B306-308

133-0121-5426

Powered by  MetInfo  7.5.0